Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

GLP-1 receptor agonist medications like Ozempic may do more ... and lifestyle trends, with work appearing in Men’s Health, Women’s Health, Self, Glamour, and more. She has a master’s degree ...